ライフサイエンスコーパス: contraceptive

1 ral, Depo-Provera injection, patch, and ring contraceptives).

2 vide an avenue for the development of a male contraceptive.

3 baseline 203 (55%) reported use of reliable contraceptive.

4 e for the development of a non-hormonal male contraceptive.

5 get, e.g. for diabetes, glaucoma, and a male contraceptive.

6 rticularly low use of long-acting reversible contraceptives.

7 high effectiveness of long-acting reversible contraceptives.

8 Interventions/Exposures: Hormonal contraceptives.

9 e than among women who had not used hormonal contraceptives.

10 t for psychiatrists who treat women desiring contraceptives.

11 tion was found in women who did not use oral contraceptives.

12 ficant up to 35 years after last use of oral contraceptives.

13 t address adherence problems noted with oral contraceptives.

14 ng risk factor for CVT in women who use oral contraceptives.

15 logical effects to injectable progestin-only contraceptives.

16 sis on development of long-acting reversible contraceptives.

17 seline, 26% of women were using any hormonal contraceptives.

18 The majority of women choose combined oral contraceptives.

19 formin vs placebo or estrogen-progestin oral contraceptives, (3) insulin-sensitizing agents, and (4)

20 rt, 152 women used injectable progestin-only contraceptives, 43 used other forms of contraception, an

21 1.5%] vs 3220 [52.5%]), more often used oral contraceptives (97 [72.9%] vs 758 [23.5%] of women), and

22 examine changes in the number of claims for contraceptives according to method for 2 years before an

23 Oral contraceptives (adjusted relative risk [RR], 2.02 [95% c

24 d the wide-spread clinical use of EE as oral contraceptive adjuvant, the impact of these estrogenic e

25 evidence linking such communication to youth contraceptive and condom use has not been empirically sy

26 ugh studies reveal many women do not receive contraceptive and preconceptual counselling.

27 ccessfully develop an approved male hormonal contraceptive and to identify long-term side-effects.

28 for the rational development of non-hormonal contraceptives and fertility treatments for humans and o

29 eduction, 35.5%) for long-acting, reversible contraceptives and from 6832 to 4708 (relative reduction

30 Estradiol-based contraceptives and hormonal replacement therapy predispo

31 ol, is prescribed commonly and found in oral contraceptives and hormone replacement therapies.

32 tractive targets for both the development of contraceptives and infertility treatment drugs.

33 hose impact is strongly enhanced by hormonal contraceptives and mediated by sex hormone-binding globu

34 ith aura, young age, female sex, use of oral contraceptives and smoking habits.

35 have been raised about progestin-containing contraceptives and the risk of human immunodeficiency vi

36 C (intrauterine device or implant), (2) oral contraceptives, and (3) Depo-Provera, patch, or ring.

37 livery 15 years earlier, was not taking oral contraceptives, and had no history to suggest past deep

38 chological distress, current use of hormonal contraceptives, and hospital centre.

39 than among women who had never used hormonal contraceptives, and this risk increased with longer dura

40 proliferative estrogen signaling (i.e., oral contraceptives/antagonization of human gonadotropin-rele

41 progestin-only therapy, or combined hormonal contraceptives are effective for controlling HMB.

42 interactions between psychotropic drugs and contraceptives are rare, clozapine, anticonvulsants, and

43 Long-acting reversible contraceptives are seldom used in Latin America and the

44 Among women using injectable contraceptives at baseline, we observed rates of contrac

45 Intake of oral contraceptives (beta, 0.150; 95% CI, 0.0649 to 0.236) an

46 ortant progress increasing the use of modern contraceptives, but important inequalities remain.

47 al of 120 million additional users of modern contraceptives by 2020 in the select study settings.

48 e presented in our study, we argue that oral contraceptives can dramatically reduce women's risk of o

49 Short-acting contraception methods (eg, oral contraceptives) can be used as a temporary bridge to pro

50 specified proportion of women attending for contraceptive care to improve contraceptive choice.

51 attending for contraceptive care to improve contraceptive choice.

52 The authors discuss contraceptive choices and their effectiveness, side effe

53 ve Use, provided the structure for review of contraceptive choices.

54 thisterone enanthate (Net-En), combined oral contraceptives (COC) or etonorgesterol/ethinyl estradiol

55 ) or levonorgestrel-containing combined oral contraceptives (COC, n = 12), and from women not using c

56 r and (ii) pristimerin and lupeol can act as contraceptive compounds by averting sperm hyperactivatio

57 elines state that use of estrogen-containing contraceptives confers an "unacceptable health risk" dur

58 Hormonal based contraceptives contain a dose of a synthetic progesteron

59 ptives, there was a reduction in the rate of contraceptive continuation and an increase in the rate o

60 raceptives at baseline, we observed rates of contraceptive continuation through the program and of ch

61 ives (COC, n = 12), and from women not using contraceptives (control group, n = 11).

62 rove highly beneficial in developing precise contraceptive delivery system, to enhance the quality of

63 Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) i

64 The hormonal contraceptive depot medroxyprogesterone acetate (DMPA) m

65 In order to accelerate contraceptive development, we screened the comprehensive

66 Contraceptive drugs intended for family planning are use

67 ort across the blood-testis barrier (BTB) of contraceptive drugs or to treat male infertility.

68 The contraceptive effectiveness of intrauterine devices (IUD

69 an noninfected peers, yet concerns regarding contraceptive efficacy and interaction with antiretrovir

70 l triggers included estrogen-containing oral contraceptives (eOC), hormonal replacement therapy, or a

71 ot increase gVL or pVL and had low levels of contraceptive failure and associated PID compared with t

72 received efavirenz-based ART, accompanied by contraceptive failures.

73 contraceptive vaginal system is an effective contraceptive for 13 consecutive cycles of use.

74 higher among the women who had used hormonal contraceptives for 5 years or more than among women who

75 th CD receiving the combination type of oral contraceptives for at least 1 year, 1 extra surgery is r

76 ing the safety and effectiveness of hormonal contraceptives for primary prevention of asthma will be

77 ncy virus-uninfected females, not taking any contraceptives, from Cape Town, South Africa, to evaluat

78 sum was used to test for differences between contraceptive groups.

79 (age range, 15-19 years) using combined oral contraceptives had an RR of a first use of an antidepres

80 mpared with nonusers, users of combined oral contraceptives had an RR of first use of an antidepressa

81 The use of injectable progestin-only contraceptives has been associated with increased risk o

82 duced amenorrhea, use of estrogen-containing contraceptives, having given birth in the prior year, an

83 ed with nonuse, previous use of any hormonal contraceptives (hazard ratio [HR], 0.70; 95% CI, 0.68-0.

84 However, hormonal contraceptive (HC) use may influence HIV risk through ch

85 nal studies suggest that injectable hormonal contraceptives (HC) increase HIV risk, although their ef

86 nal studies suggest that injectable hormonal contraceptives (HCs) increase the HIV risk, although the

87 orporated transdermal patches containing the contraceptive hormone levonorgestrel (LNG) into an earri

88 r the continuous release of levonorgestrel-a contraceptive hormone.

89 Sustained-release formulations of contraceptive hormones are available, yet typically requ

90 ovel method of drug delivery, especially for contraceptive hormones, that has the potential to improv

91 This is especially true for contraceptive hormones, which provide almost perfect pre

92 been investigated for controlled release of contraceptive hormones.

93 d pack-years), alcohol, family history, oral contraceptive, hormones, physical activity, and diet.

94 Contraceptive implants and intrauterine devices (IUDs) a

95 Although long-acting reversible contraceptives (implants, intrauterine devices) are asso

96 clinical studies and found to act as an oral contraceptive in combination with a progestin, without i

97 Women using no long-term contraceptive in the luteal phase of the menstrual cycle

98 and adolescent girls become users of modern contraceptives in 69 of the world's poorest countries by

99 to settings without improved availability of contraceptives in publicly funded facilities.

100 y inform the selection and use of injectable contraceptives in tuberculosis-endemic countries.

101 use of hormone replacement therapy, and oral contraceptives in women.

102 Promotion and provision of reliable contraceptives increased the proportion using them and c

103 the RR estimates for users of combined oral contraceptives increased to 1.7 (95% CI, 1.66-1.71).

104 Reliable contraceptives (injectable Depot Medroxyprogesterone Ace

105 women who returned for a subsequent on-time contraceptive injection decreased from 56.9% among those

106 7.5 vs 19.2 years +/- 9.2; P = .001) of oral contraceptive intake.

107 -31, 32-40), and recent injectable progestin contraceptive (IPC) exposure, and provided the allocated

108 hese organisations' ability to supply modern contraceptives, it could have the unintended consequence

109 pared gVL, plasma VL (pVL), and intrauterine contraceptive (IUC) continuation between the levonorgest

110 tential to become pregnant, to improve their contraceptive knowledge and behaviours.

111 Contraceptive knowledge was high, with over 90% of both

112 ear-olds were using a long-acting reversible contraceptive (LARC; 51.7%, 95% CI 41.1-61.9) compared t

113 ne devices (IUDs) are long-acting reversible contraceptives (LARCs) that are known to be highly effec

114 rone or a synthetic analog found in hormonal contraceptives, levonorgestrel, impacts sequential influ

115 dometriosis drug approvals to date have been contraceptive, limiting their use in women of child-bear

116 Hormonal contraceptives may increase genital tract HIV viral load

117 of the widely used progestin-only injectable contraceptives, medroxyprogesterone acetate (MPA) and no

118 Development Goals targets for education and contraceptive met need would result in a global populati

119 walk function of educational attainment and contraceptive met need.

120 pace of change in educational attainment and contraceptive met need.

121 Contraceptive method at last sexual intercourse was asse

122 en in need of contraception who were using a contraceptive method at the time of the survey.

123 9 years who (or whose partners) were using a contraceptive method at the time of the survey.

124 wanting to conceive, and not using a modern contraceptive method decreased over time.

125 This new product adds to the contraceptive method mix and the 1-year duration of use

126 We support efforts to increase the contraceptive method mix for all women, regardless of HI

127 ngage patients and ensure that they choose a contraceptive method that aligns with their reproductive

128 However, roughly 20% of couples using a contraceptive method worldwide, and up to 80% in some co

129 oral contraceptive or another less effective contraceptive method.

130 both groups able to name at least one modern contraceptive method.

131 We assessed rates of contraceptive-method provision, method continuation thro

132 compared with users of moderately effective contraceptive methods (ie, oral, Depo-Provera injection,

133 early initiation, and continuation of modern contraceptive methods among recently postpartum WLWH del

134 responsibility, but available male-directed contraceptive methods are either not easily reversible (

135 e 120 million additional women to use modern contraceptive methods by 2020 in the world's 69 poorest

136 ted infections related to low use of barrier contraceptive methods during sexual encounters with men.

137 e number of claims for short-acting hormonal contraceptive methods during this period.

138 LARC devices constitute first-line contraceptive methods for adolescents.

139 Similar proportions of women changed contraceptive methods over the 6-month follow-up in the

140 co was the only country in which long-acting contraceptive methods were more frequently used than sho

141 raception (LARC) is among the most effective contraceptive methods, but uptake remains low even in hi

142 more than 10% of women adopting long-acting contraceptive methods.

143 We included the following as modern contraceptive methods: oral pills, intrauterine devices,

144 tive age defined by their marital status and contraceptive need and use, and the sizes of these subgr

145 untries to examine change in satisfaction of contraceptive need from a contextual perspective.

146 s showed that country-level variation in met contraceptive need was largely explained by a single com

147 s age at menarche, subtracting years of oral contraceptive (OC) use and 1 year per pregnancy.

148 women) minus age at menarche, years of oral contraceptive (OC) use, and one year per pregnancy.

149 e of exogenous hormones, in the form of oral contraceptives (OCs), has been linked consistently to ri

150 o be exposed, such as men in studies on oral contraceptives (OCs).

151 to better understand mechanisms of action of contraceptives of by studying their effects on endometri

152 story.IMPORTANCE The impact of hormone-based contraceptives on the outcome of infectious diseases out

153 The impact of hormonal contraceptives on the risk for depression is controversi

154 is necessary to normalize offering LARC as a contraceptive option and improve its uptake among adoles

155 human health and the importance of DMPA as a contraceptive option to prevent unintended pregnancy.

156 icians carefully should evaluate and monitor contraceptive options among women with established CD.

157 populations can also be offered appropriate contraceptive options inclusive of LARC.

158 el about LARC even before suggesting an oral contraceptive or another less effective contraceptive me

159 Safer sex behavior, including use of contraceptives or condoms.

160 d followed up women who did not use hormonal contraceptives or desired pregnancy after study completi

161 ch can be managed with short courses of oral contraceptives or nonsteroidal anti-inflammatory drugs.

162 cation revealed that, in women who used oral contraceptives, overweight and obesity were associated w

163 ells) compared with women using no long-term contraceptive (p=0.0241).

164 8 (relative reduction, 31.1%) for injectable contraceptives (P<0.001 for both comparisons).

165 ical modeling to understand better how these contraceptive paradigms prevent ovulation, special focus

166 et, smoking, alcohol intake, and use of oral contraceptives (per 1-unit increase in BMI, mean differe

167 ) ) women taking a combined, monophasic oral contraceptive pill (OCP) (>=12 months) during exercise i

168 pletely resolved after cessation of the oral contraceptive pill (OCP) and associated adenoma regressi

169 the associations between sex hormones, oral contraceptive pill (OCP) use, systemic inflammation and

170 chronically take a combined, monophasic oral contraceptive pill (OCP).

171 menopausal females were not matched for oral contraceptive pill use.

172 ith sex and 66 molecules varied between oral contraceptive pill users, postmenopausal females, and fe

173 rings (CCVR; NuvaRing(R)), and combined oral contraceptive pills (COCPs) on cervical Th17 cells and c

174 al rings (CCVR; NuvaRing), and combined oral contraceptive pills (COCPs) on cervical Th17 cells and c

175 To evaluate the effect of oral contraceptive pills (OCP) on the macula, the retinal ner

176 a substantial advance from traditional oral contraceptive pills, to improve upon safety, efficiency,

177 grammes that address the critical gap in the contraceptive portfolio as well as uncover novel human s

178 to our knowledge one of the first to measure contraceptive prevalence among adolescents in a humanita

179 We calculated contraceptive prevalence and demand for family planning

180 elative inequalities were estimated both for contraceptive prevalence and demand for family planning

181 to 2019 and projections from 2019 to 2030 of contraceptive prevalence and unmet need for family plann

182 ruct estimates and projections of the modern contraceptive prevalence rate (mCPR), unmet need for, an

183 fter 2012, to ascertain the trends in modern contraceptive prevalence rates among all women aged 15-4

184 The annual rates of changes in modern contraceptive prevalence rates among all women of reprod

185 timated the annual rate of changes in modern contraceptive prevalence rates for each country setting

186 ng the pre-2012 annual growth rate of modern contraceptive prevalence rates from an estimated 0.7 to

187 hted average annual rate of change in modern contraceptive prevalence rates in all women across all n

188 We examined the post-Summit trends in modern contraceptive prevalence rates in nine settings in eight

189 Contraceptive prevalence was defined as the percentage o

190 The lowest modern contraceptive prevalence was observed in Haiti (31.3%) a

191 a, Cuba, and Paraguay had over 70% of modern contraceptive prevalence with low absolute inequalities.

192 y (NCT02404038), comparing acceptability and contraceptive product preference as a proxy for HIV prev

193 ontinue providing women safe and easy to use contraceptive products.

194 Gestodene is a human contraceptive progestin and a potent activator of fish a

195 In this study, the ability of the contraceptive progestin levonorgestrel to bind chemicall

196 their intended use, progesterone (P4)-based contraceptives promote anti-inflammatory immune response

197 rmacists advised women to attend their usual contraceptive provider.

198 ancer than women who had never used hormonal contraceptives (relative risk, 1.21; 95% CI, 1.11 to 1.3

199 ng the number of pregnancies by provision of contraceptive services as part of a Reproductive Health

200 lth (MOH) since 2011 to provide good quality contraceptive services in public health facilities in co

201 t they will use effective contraception when contraceptive services, including short- and long-acting

202 ncial, knowledge, and structural barriers to contraceptive services.

203 d-gender cohorts and females taking hormonal contraceptives should be considered as a separate sub-co

204 tion, availability of long-acting reversible contraceptives should be expanded and their use promoted

205 lood concentrations of key hormones during a contraceptive state achieved by administering progestins

206 dvantage of the combined treatment is that a contraceptive state can be obtained at a lower dose of e

207 ensive review on controlled release hormonal contraceptive systems that include transdermal patches,

208 esults should enable the development of male contraceptives targeting one or both enzymes.

209 making these proteins promising non-hormonal contraceptive targets [1,3].

210 l access to reproductive health services and contraceptive technologies, advancing women's education,

211 ently or recently used contemporary hormonal contraceptives than among women who had never used hormo

212 Among women using injectable contraceptives, the percentage of women who returned for

213 Compared with women who never used hormonal contraceptives, the relative risk among current and rece

214 Six months after starting use of hormonal contraceptives, the RR of antidepressant use peaked at 1

215 For women using injectable contraceptives, there was a reduction in the rate of con

216 cation period, which is well above the human contraceptive threshold concentration of 200 pg/ml.

217 f periods, but remained well above the human contraceptive threshold.

218 ombining antiretrovirals (ARV) and progestin contraceptives to prevent HIV infection and pregnancy.

219 d to allow therapeutic drugs, including male contraceptives, to be transported across the BTB and mor

220 ithin the range indicative of efficacy for a contraceptive under a woman's control.

221 H-indazole-3-carbohydrazide (adjudin, a male contraceptive under development) causes permanent infert

222 rogram appeared to increase early postpartum contraceptive uptake and continuation in a setting in wh

223 ociated with lower gender inequality, higher contraceptive uptake, and lower maternal and child morta

224 Current modern contraceptive use (16.5%, 95% CI 14.7-18.4) was similar

225 ediately (<=2 years) after discontinued oral contraceptive use (HR = 1.55; 95% CI, 1.06-2.28), wherea

226 ectomy (CD), antibiotic exposure (IBD), oral contraceptive use (IBD), consumption of soft drinks (UC)

227 Heterogeneity was observed with oral contraceptive use (P (interaction) = 0.03), where the in

228 C components: number of pregnancies and oral contraceptive use [1.08 (1.04-1.12)].

229 In this study, we analyzed contraceptive use among sexually active young women aged

230 The association between hormonal contraceptive use and a first suicide attempt peaked aft

231 ime-dependent effects between long-term oral contraceptive use and cancer risk.

232 The odds ratio of hormonal contraceptive use and IIH was 0.55 (95% conficence inter

233 In analysis that adjusted for hormonal contraceptive use and marital status, women reporting mu

234 ome adjustments were made, underreporting of contraceptive use and needs is likely, especially among

235 sidered potential mediators between hormonal contraceptive use and risk of suicide attempt.

236 thors assessed associations between hormonal contraceptive use and suicide attempt and suicide in a n

237 We investigated reliable contraceptive use at baseline and six months in key-popu

238 rs) was an independent predictor of reliable contraceptive use at both time points while other factor

239 c diagnoses, antidepressant use, or hormonal contraceptive use before age 15 and who turned 15 during

240 We separated survey data for modern contraceptive use by type of contraception used (long-ac

241 Contraceptive use data were recorded at baseline and fol

242 of menorrhagia, which was managed with oral contraceptive use for 20 years; this was stopped in 2013

243 Oral contraceptive use has been suggested to influence the ri

244 The rise in contraceptive use has largely been driven by short-actin

245 5% uncertainty interval 46.4-62.1) in modern contraceptive use in 2015 between subregions.

246 Little evidence on adolescent contraceptive use in humanitarian settings is available.

247 ssessed the prevalence and demand for modern contraceptive use in Latin America and the Caribbean wit

248 Injectable contraceptive use is common, with 74 million users world

249 To prevent pregnancy in trials, reliable contraceptive use is key.

250 iation by combined estrogen/progestogen oral contraceptive use or pregnancy.

251 living with HIV (WLHIV) have lower rates of contraceptive use than noninfected peers, yet concerns r

252 re the highest percentage increase in modern contraceptive use to achieve 75% demand satisfied with m

253 Hormonal contraceptive use was associated with reduced risk of ne

254 Current hormonal contraceptive use was positively associated with inciden

255 Although contraceptive use was rising rapidly in Ethiopia during

256 udies with adjustment for smoking, BMI, oral contraceptive use, and parity, compared to studies witho

257 evels and trends in the prevalence of modern contraceptive use, and unmet need and demand for family

258 ling, with adjustment for age, smoking, oral contraceptive use, body mass index, menopausal status, p

259 ts available to serve as proxies (e.g., oral contraceptive use, hormone replacement therapy), and the

260 smoking, physical activity, menopause, oral contraceptive use, hormone therapy, and field center.

261 We sought to investigate whether hormonal contraceptive use, its subtypes, and duration of use wer

262 ity, age at first birth, breastfeeding, oral contraceptive use, or ever use of postmenopausal hormone

263 mendations, Medical Eligibility Criteria for Contraceptive Use, provided the structure for review of

264 ake more informed decisions considering oral contraceptive use, thus constituting an important step t

265 year and adjusted for age, parity, and oral contraceptive use, we assessed associations for all inva

266 current smoking status, and recent hormonal contraceptive use, women with low AMH values (<0.7 ng/mL

267 tivity, demand for contraception, and modern contraceptive use.

268 tivity, demand for contraception, and modern contraceptive use.

269 exceeded pre-FP2020 expectations for modern contraceptive use.

270 gun childbearing were associated with modern contraceptive use.

271 lling for menstrual cycle phase and hormonal contraceptive use.

272 cancer, ethnicity, smoking status, and oral contraceptive use.

273 on as a potential adverse effect of hormonal contraceptive use.

274 ing reversible contraception and dual method contraceptive use; message content in the control group

275 ess likely to use condoms compared with oral contraceptive users (adjusted prevalence ratio [aPR], 0.

276 lf-reported DMPA users (n = 23), nonhormonal contraceptive users (n = 63), and women who practice vag

277 ted 15.7% (95% UI 13.4%-19.4%) of all modern contraceptive users and 16.0% (95% UI 12.9%-22.1%) of wo

278 or lower rates of mood symptoms in hormonal contraceptive users compared with nonusers.

279 HIV-negative injectable progestin-only contraceptive users had 3.92 times the frequency of cerv

280 or etonorgesterol/ethinyl estradiol combined contraceptive vaginal ring (CCVR) for 16 weeks, then cro

281 norethisterone oenanthate (NET-EN), combined contraceptive vaginal rings (CCVR; NuvaRing(R)), and com

282 norethisterone oenanthate (NET-EN), combined contraceptive vaginal rings (CCVR; NuvaRing), and combin

283 We evaluated the efficacy of this contraceptive vaginal system and return to menses or pre

284 A ring-shaped, contraceptive vaginal system designed to last 1 year (13

285 The segesterone acetate and ethinylestradiol contraceptive vaginal system is an effective contracepti

286 out segesterone acetate and ethinylestradiol contraceptive vaginal system schedule for up to 13 cycle

287 The Kaplan-Meier analysis revealed the contraceptive vaginal system was 97.5% effective, which

288 arious oral combination (estrogen-progestin) contraceptives varied between 1.0 and 1.6.

289 Effects did not differ for contraceptive vs condom use or among longitudinal vs cro

290 ong current and recent users of any hormonal contraceptive was 13 (95% CI, 10 to 16) per 100,000 pers

291 ignificantly lower when an intravaginal ring contraceptive was combined with efavirenz-based ART.

292 Use of long-acting reversible contraceptives was below 10% in 17 of the 23 countries.

293 The use of OCPs and other hormonal contraceptives was compared to controls matched for age,

294 Consistent with regulatory requirements for contraceptives, we calculated the Pearl Index for women

295 Women using injectable progestin-only contraceptives were at substantially higher risk of acqu

296 OCP and other hormonal contraceptives were not significantly associated with a

297 In particular, differences in use of oral contraceptives (which it was not possible to control for

298 The LNG-IUS appears to be a safe contraceptive with regard to HIV disease and may be a hi

299 onorgestrel subdermal implants are preferred contraceptives with an expected failure rate of <1% over

300 5 years of age, 11 (20.8%) had used hormonal contraceptives within <=30 days of the date of IIH diagn